Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product RevenueGlobeNewsWire • 01/12/26
AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's AgitationZacks Investment Research • 01/02/26
Axsome Therapeutics Stock Jumps After FDA Grants Priority Review For Alzheimer's Agitation DrugInvestors Business Daily • 12/31/25
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA SubmissionGlobeNewsWire • 12/31/25
Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference TranscriptSeeking Alpha • 12/04/25
Axsome (AXSM) Up 5.3% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/03/25
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of EpilepsyGlobeNewsWire • 11/06/25
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome TherapeuticsGlobeNewsWire • 11/06/25
Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis ChangerSeeking Alpha • 11/05/25
Axsome Therapeutics Stock In A Buy Zone. Analysts See Profit On The Horizon.Investors Business Daily • 11/05/25
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity SalesZacks Investment Research • 11/04/25
Axsome Therapeutics (AXSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 10/27/25
Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their RightsBusiness Wire • 10/24/25
Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy RatingSeeking Alpha • 10/10/25